Auto-antibodies as possible markers and mediators of ischemic, dilated, and rhythmic cardiopathies

Current Drug Targets

Volumn 16, Issue 4, 2015, Pages 342-360

  Satta, Nathalie ^a,b   Vuilleumier, Nicolas ^a,b  

^a Department of Human Protein Sciences ^*  (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Auto antibodies; Auto immune disease; Cardiomyopathies; Cardiovascular disease

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); APOLIPOPROTEIN A1; AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; CD14 ANTIGEN; CHAPERONIN 60; COR 1 PEPTIDE; CYCLOPEPTIDE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 8; LIPOCORTIN 2; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC M2 RECEPTOR; MYOSIN; PHOSPHOLIPID ANTIBODY; PHOSPHORYLCHOLINE; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; AUTACOID; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHAGAS DISEASE; CLINICAL TRIAL (TOPIC); HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; IMMUNOGENICITY; INFLAMMATION; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PROGNOSIS; RISK; SENSITIVITY AND SPECIFICITY; ANIMAL; ARRHYTHMIAS, CARDIAC; AUTOIMMUNITY; BLOOD; CARDIOMYOPATHY, DILATED; IMMUNOLOGY; MYOCARDIAL ISCHEMIA; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; ARRHYTHMIAS, CARDIAC; ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOIMMUNITY; BIOMARKERS; CARDIOMYOPATHY, DILATED; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84928892925     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141125122416     Document Type: Article

References (251)

1. [1] Murphy TP, Dhangana R, Pencina MJ, Zafar AM, D'Agostino RB. Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment. Atherosclerosis 2011; 216: 452-7.
2. [2] Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327: 1267.
3. [3] Hansson GK, Nilsson J. Introduction: atherosclerosis as inflamma-tion: a controversial concept becomes accepted. J Intern Med 2008; 263: 462-3.
4. [4] Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
5. [5] Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
6. [6] Hansson GK, Hermansson A. The immune system in atherosclero- sis. Nat Immunol 2011; 12: 204-12.
7. [7] Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphosphol-ipid antibody profile. J Thromb Haemost 2013; 11: 1527-31.
8. [8] Gomes Quindere AL, Benevides NM, Carbone F, Mach F, Vuille- umier N, Montecucco F. Update on selective treatments targeting neutrophilic inflammation in atherogenesis and atherothrombosis. Thromb Haemost 2014; 111: 634-46.
9. [9] Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-8.
10. [10] van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
11. [11] Malgor R, Bhatt PM, Connolly BA, et al. Wnt5a, TLR2 and TLR4 are elevated in advanced human atherosclerotic lesions. Inflamm Res 2014; 63: 277-85.
12. [12] Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol 2014; 9: 73-102.
13. [13] Matsuura E, Kobayashi K, Lopez LR. Atherosclerosis in autoimmune diseases. Curr Rheumatol Rep 2009; 11: 61-9.
14. [14] Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allergy Immunol 2009; 37: 20-8.
15. [15] Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite an-tiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
16. [16] Bevers EM, Galli M. Beta 2-glycoprotein I for binding of anticar-diolipin antibodies to cardiolipin. Lancet 1990; 336: 952-3.
17. [17] Pozzi N, Acquasaliente L, Frasson R, et al. beta2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions. J Thromb Haemost 2013; 11: 1093-102.
18. [18] Takeuchi R, Atsumi T, Ieko M, et al. Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency. Blood 2000; 96: 1594-5.
19. [19] Agar C, de Groot PG, Morgelin M, et al. beta(2)-glycoprotein I: a novel component of innate immunity. Blood 2011; 117: 6939-47.
20. [20] Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-43.
21. [21] Kobayashi K, Kishi M, Atsumi T, et al. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003; 44: 716-26.
22. [22] Kobayashi K, Lopez LR, Matsuura E. Atherogenic antiphosphol-ipid antibodies in antiphospholipid syndrome. Ann N Y Acad Sci 2007; 1108: 489-96.
23. [23] Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-90.
24. [24] Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95: 15542-6.
25. [25] McNeeley PA, Dlott JS, Furie RA, et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001; 86: 590-5.
26. [26] de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-5.
27. [27] de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-73.
28. [28] Banzato A, Pozzi N, Frasson R, et al. Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res 2011; 128: 583-6.
29. [29] Mondejar R, Gonzalez-Rodriguez C, Toyos Saenzde Miera FJ, et al. Role of antiphospholipid score and anti-beta2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 2014; 431: 174-8.
30. [30] Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multi-centre prospective study of 1000 patients. Ann Rheum Dis 2014 [Epub ahead of print].
31. [31] Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8: 998-1005.
32. [32] Meroni PL, Peyvandi F, Foco L, et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premeno-pausal women. J Thromb Haemost 2007; 5: 2421-8.
33. [33] Davies JO, Hunt BJ. Myocardial infarction in young patients without coronary atherosclerosis: assume primary antiphospholipid syndrome until proved otherwise. Int J Clin Pract 2007; 61: 379-84.
34. [34] Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Rado-vanovic S, Marisavljevic D. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J 2014; 16: 162-7.
35. [35] Ertas F, Can O, Acet H, Ozbakkaloglu M. The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study. Postepy Kardiol Interwencyjnej 2013; 9(4): 328-31.
36. [36] Artenjak A, Lakota K, Frank M, et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev 2012; 11: 873-82.
37. 37[] Sciascia S, Sanna G, Khamashta MA, et al. The estimated frequency of antiphospholipid antibodies in young adults with cere-brovascular events: a systematic review. Ann Rheum Dis 2014 Jun 18. pii: annrheumdis-2014-205663.
38. [38] Ali HY, Abdullah ZA. Anti-beta(2)-glycoprotein I autoantibody expression as a potential biomarker for strokes in patients with anti-phospholipid syndrome. J Immunotoxicol 2008; 5: 173-7.
39. [39] Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004; 121: 142-9.
40. [40] Majka DS, Liu K, Pope RM, et al. Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Inflamm Res 2013; 62: 919-27.
41. [41] Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014; 13: 595-608.
42. [42] Du VX, Kelchtermans H, de Groot PG, de Laat B. From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res 2013; 132: 319-26.
43. [43] Giannakopoulos B, Krilis SA. The pathogenesis of the antiphos-pholipid syndrome. N Engl J Med 2013; 368: 1033-44.
44. [44] Brandt KJ, Kruithof EK, de Moerloose P. Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res 2013; 132: 408-13.
45. [45] Agostinis C, Durigutto P, Sblattero D, et al. A non-complement-fixing antibody to beta2 glycoprotein I as a novel therapy for an-tiphospholipid syndrome. Blood. 2014; 123: 3478-87.
46. [46] Benhamou Y, Bellien J, Armengol G, et al. Role of toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol 2014; 66(11): 3210-20.
47. [47] Xie H, Zhou H, Wang H, et al. Anti-beta(2)GPI/beta(2)GPI induced TF and TNF-alpha expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol 2013; 53: 246-54.
48. [48] Satta N, Kruithof EK, Fickentscher C, et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood 2011; 117: 5523-31.
49. [49] Dunoyer-Geindre S, Kwak BR, Pelli G, et al. Immunization of LDL receptor-deficient mice with beta2-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques. Thromb Haemost 2007; 97: 129-38.
50. [50] Wang XX, Lv XX, Wang JP, et al. Blocking TLR2 activity diminishes and stabilizes advanced atherosclerotic lesions in apolipopro-tein E-deficient mice. Acta Pharmacol Sin 2013; 34: 1025-35.
51. [51] Zhang X, Xie Y, Zhou H, et al. Involvement of TLR4 in Oxidized LDL/betaGPI/Anti-betaGPI-Induced Transformation of Macro-phages to Foam Cells. J Atheroscler Thromb 2014; 21(11): 1140-51.
52. [52] Conti F, Spinelli FR, Alessandri C, et al. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on beta2GPI-specific T cell response. Arterioscler Thromb Vasc Biol 2014; 34: 661-8.
53. [53] Cederholm A, Svenungsson E, Jensen-Urstad K, et al. Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25: 198-203.
54. [54] de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109: 1490-4.
55. [55] de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008; 19: 757-64.
56. [56] Chaturvedi S, McCrae KR. Recent advances in the antiphosphol-ipid antibody syndrome. Curr Opin Hematol 2014; 21: 371-9.
57. [57] Ostertag MV, Liu X, Henderson V, Pierangeli SS. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphos-pholipid-mediated thrombosis in mice. Lupus 2006; 15: 358-65.
58. [58] Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009; 7: 833-42.
59. [59] Kolyada A, Porter A, Beglova N. Inhibition of thrombotic properties of persistent autoimmune anti-beta2GPI antibodies in the mouse model of antiphospholipid syndrome. Blood 2014; 123: 1090-7.
60. [60] Zhou H, Sheng L, Wang H, et al. Anti-beta2GPI/beta2GPI stimulates activation of THP-1 cells through TLR4/MD-2/MyD88 and NF-kappaB signaling pathways. Thromb Res 2013; 132: 742-9.
61. [61] Akkerman A, Huang W, Wang X, et al. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 2004; 37: 445-51.
62. [62] Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014; 73: 1176-80.
63. [63] Cohen IR. Autoantibody repertoires, natural biomarkers, and system controllers. Trends Immunol 2013; 34: 620-5.
64. [64] Pfister G, Stroh CM, Perschinka H, et al. Detection of HSP60 on the membrane surface of stressed human endothelial cells by atomic force and confocal microscopy. J Cell Sci 2005; 118: 1587-94.
65. [65] Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, Wick G. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pa-thol 1993; 142: 1927-37.
66. [66] Xu Q, Schett G, Perschinka H, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000; 102: 14-20.
67. [67] Heltai K, Kis Z, Burian K, et al. Elevated antibody levels against Chlamydia pneumoniae, human HSP60 and mycobacterial HSP65 are independent risk factors in myocardial infarction and ischaemic heart disease. Atherosclerosis 2004; 173: 339-46.
68. [68] Zhang X, He MA, Cheng L, et al. Joint effects of antibody to heat shock protein 60, hypertension, and diabetes on risk of coronary heart disease in Chinese. Clin Chem 2008; 54: 1046-52.
69. [69] Gromadzka G, Zielinska J, Ryglewicz D, Fiszer U, Czlonkowska A. Elevated levels of anti-heat shock protein antibodies in patients with cerebral ischemia. Cerebrovasc Dis 2001; 12: 235-9.
70. [70] Bodolay E, Prohaszka Z, Paragh G, et al. Increased levels of anti-heat-shock protein 60 (anti-Hsp60) indicate endothelial dysfunction, atherosclerosis and cardiovascular diseases in patients with mixed connective tissue disease. Immunol Res 2014; 60(1): 50-9.
71. [71] Zhang X, He M, Cheng L, et al. Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese. Circulation 2008; 118: 2687-93.
72. [72] Bason C, Corrocher R, Lunardi C, et al. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 2003; 362: 1971-7.
73. [73] Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneu-moniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102: 833-9.
74. [74] Burian K, Kis Z, Virok D, et al. Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneu-moniae infection in the development of coronary atherosclerosis. Circulation 2001; 103: 1503-8.
75. [75] Knoflach M, Kiechl S, Mayrl B, et al. T-cell reactivity against HSP60 relates to early but not advanced atherosclerosis. Atherosclerosis 2007; 195: 333-8.
76. [76] Knoflach M, Kiechl S, Penz D, et al. Cardiovascular risk factors and atherosclerosis in young women: atherosclerosis risk factors in female youngsters (ARFY study). Stroke 2009; 40: 1063-9.
77. [77] Almanzar G, Ollinger R, Leuenberger J, et al. Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions. J Autoimmun. 2012; 39: 441-50.
78. [78] Dieude M, Gillis MA, Theoret JF, et al. Autoantibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis. J Thromb Haemost 2009; 7: 710-9.
79. [79] Foteinos G, Afzal AR, Mandal K, Jahangiri M, Xu Q. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipo-protein E-deficient mice via endothelial damage. Circulation 2005; 112: 1206-13.
80. [80] Yokota S, Minota S, Fujii N. Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. Int Immunol 2006; 18: 573-80.
81. [81] Zanin-Zhorov A, Cohen IR. Signaling via TLR2 and TLR4 Directly Down-Regulates T Cell Effector Functions: The Regulatory Face of Danger Signals. Front Immunol 2013; 4: 211.
82. [82] Xiao Q, Mandal K, Schett G, et al. Association of serum-soluble heat shock protein 60 with carotid atherosclerosis: clinical significance determined in a follow-up study. Stroke 2005; 36: 2571-6.
83. [83] van Puijvelde GH, van Es T, van Wanrooij EJ, et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2677-83.
84. [84] Lu X, Chen D, Endresz V, et al. Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice. Atherosclerosis 2010; 212: 472-80.
85. [85] Li J, Zhao X, Zhang S, Wang S, Du P, Qi G. ApoB-100 and HSP60 peptides exert a synergetic role in inhibiting early atherosclerosis in immunized ApoE-null mice. Protein Pept Lett 2011; 18: 733-40.
86. [86] Moohebati M, Bidmeshgi S, Azarpazhooh MR, et al. Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial. Clin Biochem 2011; 44: 192-7.
87. [87] Guisasola MC, Dulin E, Almendral J, Garcia-Barreno P. Reduction of heat shock protein antibody levels by statin therapy. Lipids 2009; 44: 317-24.
88. [88] Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2010; 208: 3-9.
89. [89] Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004; 44: 1429-35.
90. [90] Schaefer EJ, Santos RD, Asztalos BF. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 2010; 21: 289-97.
91. [91] Teixeira PC, Cutler P, Vuilleumier N. Autoantibodies to apolipo-protein A-1 in cardiovascular diseases: current perspectives. Clin Dev Immunol 2012; 2012: 868251.
92. [92] Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of antibodies to the cholesterol transport protein apol-ipoprotein A1 in patients with SLE. Lupus 1998; 7: 355-60.
93. [93] Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2003; 42: 893-9.
94. [94] Shoenfeld Y, Szyper-Kravitz M, Witte T, et al. Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 227-39.
95. [95] O'Neill SG, Giles I, Lambrianides A, et al. Antibodies to apolipo-protein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010; 62: 845-54.
96. [96] Radwan MM, El-Lebedy D, Fouda R, Elsorougy E, Fakhry D. Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus. Clin Rheumatol 2013[Epub ahead of print].
97. [97] Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafstrom I, Frostegard J. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol 2010; 39: 447-53.
98. [98] Vuilleumier N, Bas S, Pagano S, et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010; 62: 2640-50.
99. [99] Finckh A, Courvoisier DS, Pagano S, et al. Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? Arthritis Care Res (Hoboken) 2012; 64: 817-25.
100. [100] Vuilleumier N, Reber G, James R, et al. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 2004; 23: 353-60.
101. [101] Vuilleumier N, Charbonney E, Fontao L, et al. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci (Lond) 2008; 115: 25-33.
102. [102] Vuilleumier N, Rossier MF, Pagano S, et al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 2010; 31: 815-23.
103. [103] Montecucco F, Vuilleumier N, Pagano S, et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-21.
104. [104] Vuilleumier N, Montecucco F, Spinella G, Pagano S, Bertolotto M, Pane B, et al. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. Thromb Haemost 2013; 109: 706-15.
105. [105] Pagano S, Satta N, Werling D, et al. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. J Intern Med 2012; 272: 344-57.
106. [106] Rossier MF, Pagano S, Python M, et al. Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels. Endocrinology 2012; 153: 1269-78.
107. [107] Weiss S, Oz S, Benmocha A, Dascal N. Regulation of cardiac L-type Ca(2)(+) channel CaV1.2 via the beta-adrenergic-cAMP-protein kinase A pathway: old dogmas, advances, and new uncertainties. Circ Res 2013; 113: 617-31.
108. [108] Gulia J, Navedo MF, Gui P, et al. Regulation of L-type calcium channel sparklet activity by c-Src and PKC-alpha. Am J Physiol Cell Physiol 2013; 305: C568-77.
109. [109] Batuca JR, Ames PR, Isenberg DA, Alves JD. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 137-46.
110. [110] Srivastava R, Yu S, Parks BW, Black LL, Kabarowski JH. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice. Arthritis Rheum 2011; 63: 201-11.
111. [111] Hyka N, Dayer JM, Modoux C, et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97: 2381-9.
112. [112] Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010; 55: 1283-99.
113. [113] Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipopro-tein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002; 41: 2089-96.
114. [114] Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipo-protein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001; 103: 3047-50.
115. [115] Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-300.
116. [116] Leman LJ, Maryanoff BE, Ghadiri MR. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem 2014; 57: 2169-96.
117. [117] Teixeira PC, Ducret A, Ferber P, et al. Definition of human apol-ipoprotein a-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases. J Biol Chem 2014; 289: 28249-59.
118. [118] Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004; 110: 2552-8.
119. [119] Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
120. [120] Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001; 37: 775-9.
121. [121] Tsai WC, Li YH, Chao TH, Chen JH. Relation between antibody against oxidized low-density lipoprotein and extent of coronary atherosclerosis. J Formos Med Assoc 2002; 101: 681-4.
122. [122] Rossi GP, Cesari M, De Toni R, et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation 2003; 108: 2467-72.
123. [123] Masztalewicz M, Nowacki P, Kotlega D, Bajer-Czajkowska A, Drechsler H. Anti-oxLDL antibodies are clinically insignificant for stroke patients. Neurol Res 2014; 36: 86-91.
124. [124] Moohebati M, Kabirirad V, Ghayour-Mobarhan M, et al. Investigation of serum oxidized low-density lipoprotein IgG levels in patients with angiographically defined coronary artery disease. Int J Vasc Med 2014; 2014: 845960.
125. [125] Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol 2010; 134: 55-65.
126. [126] Soto Y, Conde H, Aroche R, et al. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease. Hum Antibodies. 2009; 18: 109-17.
127. [127] Fredrikson GN, Hedblad B, Berglund G, et al. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 2007; 38: 1495-500.
128. [128] Mayr M, Kiechl S, Tsimikas S, et al. Oxidized low-density lipo-protein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol 2006; 47: 2436-43.
129. [129] Gomez M, Vila J, Elosua R, et al. Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population. Atherosclerosis 2014; 232: 134-40.
130. [130] Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 844-8.
131. [131] Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103: 1955-60.
132. [132] Faviou E, Vourli G, Nounopoulos C, Zachari A, Dionyssiou-Asteriou A. Circulating oxidized low density lipoprotein, autoanti-bodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease. Free Radic Res 2005; 39: 419-29.
133. [133] Lopes-Virella MF, Baker NL, Hunt KJ, et al. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis 2011; 214: 462-7.
134. [134] Hunt KJ, Baker N, Cleary P, et al. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis 2013; 231: 315-22.
135. [135] Hong D, Bai YP, Gao HC, et al. Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway. Atherosclerosis. 2014; 235: 310-7.
136. [136] Yang K, Zhang XJ, Cao LJ, et al. Toll-like receptor 4 mediates inflammatory cytokine secretion in smooth muscle cells induced by oxidized low-density lipoprotein. PLoS One 2014; 9: e95935.
137. [137] Yao S, Miao C, Tian H, et al. Endoplasmic reticulum stress promotes macrophage-derived foam cell formation by up-regulating cluster of differentiation 36 (CD36) expression. J Biol Chem 2014; 289: 4032-42.
138. [138] Chavez-Sanchez L, Garza-Reyes MG, Espinosa-Luna JE, Chavez-Rueda K, Legorreta-Haquet MV, Blanco-Favela F. The role of TLR2, TLR4 and CD36 in macrophage activation and foam cell formation in response to oxLDL in humans. Hum Immunol 2014; 75: 322-9.
139. [139] Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF, Group DER. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002; 105: 81-92.
140. [140] Oksjoki R, Kovanen PT, Lindstedt KA, Jansson B, Pentikainen MO. OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol 2006; 26: 576-83.
141. [141] Hammad SM, Twal WO, Barth JL, et al. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis. 2009; 202: 394-404.
142. [142] Svensson PA, Asea A, Englund MC, et al. Major role of HSP70 as a paracrine inducer of cytokine production in human oxidized LDL treated macrophages. Atherosclerosis 2006; 185: 32-8.
143. [143] Kobayashi K, Tada K, Itabe H, et al. Distinguished effects of an-tiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 2007; 16: 929-38.
144. [144] van Leeuwen M, Kemna MJ, de Winther MP, et al. Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice. PLoS One 2013; 8: e68039.
145. [145] Jeon YE, Seo CW, Yu ES, Lee CJ, Park SG, Jang YJ. Characterization of human monoclonal autoantibody Fab fragments against oxidized LDL. Mol Immunol 2007; 44: 827-36.
146. [146] George J, Afek A, Gilburd B, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-52.
147. [147] Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-5.
148. [148] Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immu-noglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998; 102: 910-8.
149. [149] Wu R, Shoenfeld Y, Sherer Y, et al. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations--possible immunomodulation of atherosclerosis. Autoimmunity 2003; 36: 91-7.
150. [150] van Tits LJ, Smilde TJ, van Wissen S, de Graaf J, Kastelein JJ, Stalenhoef AF. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxi-dizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholes-terolemia. J Investig Med 2004; 52: 177-84.
151. [151] Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119: 1335-49.
152. [152] Chou MY, Hartvigsen K, Hansen LF, et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med. 2008; 263: 479-88.
153. [153] Padilla ND, Ciurana C, van Oers J, Ogilvie AC, Hack CE. Levels of natural IgM antibodies against phosphorylcholine in healthy individuals and in patients undergoing isolated limb perfusion. J Immunol Methods 2004; 293: 1-11.
154. [154] Elkon KB, Silverman GJ. Naturally occurring autoantibodies to apoptotic cells. Adv Exp Med Biol. 2012; 750: 14-26.
155. [155] Frostegard J. Low level natural antibodies against phosphoryl-choline: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin Immunol 2010; 134: 47-54.
156. [156] Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006; 188: 160-6.
157. [157] Gronlund H, Hallmans G, Jansson JH, et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil 2009; 16: 382-6.
158. [158] Diepenhorst GM, Ciurana CL, Diaz Padilla N, et al. IgM antibodies against apoptotic cells and phosphorylcholine in patients with acute myocardial infarction in relation to infarct size and inflammatory response. Adv Clin Exp Med 2012; 21: 455-67.
159. [159] Sjoberg BG, Su J, Dahlbom I, et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 2009; 203: 528-32.
160. [160] Fiskesund R, Stegmayr B, Hallmans G, et al. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke 2010; 41: 607-12.
161. [161] Gleissner CA, Erbel C, Haeussler J, et al. Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. Clin Res Cardiol 2015; 104(1): 13-22.
162. [162] de Faire U, Su J, Hua X, et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun 2010; 34: 73-9.
163. [163] Gigante B, Leander K, Vikstrom M, et al. Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men. Atherosclerosis 2014; 236: 394-99.
164. [164] Gronwall C, Reynolds H, Kim JK, et al. Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus. Clin Immunol 2014; 153: 1-7.
165. [165] Ajeganova S, de Faire U, Jogestrand T, Frostegard J, Hafstrom I. Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study. J Rheumatol 2012; 39: 1146-54.
166. [166] Carrero JJ, Hua X, Stenvinkel P, et al. Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrol Dial Transplant 2009; 24: 3454-60.
167. [167] Binder CJ. Natural IgM antibodies against oxidation-specific epi-topes. J Clin Immunol 2010; 30 Suppl 1: S56-60.
168. [168] Palinski W, Horkko S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipo-protein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98: 800-14.
169. [169] Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731-40.
170. [170] Horkko S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999; 103: 117-28.
171. [171] Fiskesund R, Steen J, Amara K, et al. Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult. J Immunol 2014; 192: 4551-9.
172. [172] Fiskesund R, Su J, Bulatovic I, Vikstrom M, de Faire U, Frostegard J. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. Results Immunol 2012; 2: 13-8.
173. [173] Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-43.
174. 174[] Turunen SP, Kummu O, Wang C, et al. Immunization with malondialdehyde-modified low-density lipoprotein (LDL) reduces atherosclerosis in LDL receptor-deficient mice challenged with Porphyromonas gingivalis. Innate Immun 2014 Aug 17. pii: 1753425914542444.
175. [175] Faria-Neto JR, Chyu KY, Li X, et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006; 189: 83-90.
176. [176] de Jager SC, Kuiper J. Vaccination strategies in atherosclerosis. Thromb Haemost. 2011; 106: 796-803.
177. [177] Lamontagne F, Garant MP, Carvalho JC, Lanthier L, Smieja M, Pilon D. Pneumococcal vaccination and risk of myocardial infarction. CMAJ 2008; 179: 773-7.
178. [178] Nguyen JT, Myers N, Palaia J, Georgopoulos A, Rubins JB, Janoff EN. Humoral responses to oxidized low-density lipoprotein and related bacterial antigens after pneumococcal vaccine. Transl Res 2007; 150: 172-9.
179. [179] Damoiseaux J, Rijkers G, Tervaert JW. Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and therefore precludes an anti-atherogenic effect. Atherosclerosis 2007; 190: 10-1.
180. [180] Konstadoulakis MM, Kroumbouzou H, Tsiamis E, Trikas A, Toutouzas P. Clinical significance of antibodies against tropomy-osin, actin and myosin in patients with dilated cardiomyopathy. J Clin Lab Immunol 1993; 40: 61-7.
181. [181] Caforio AL, Goldman JH, Haven AJ, Baig KM, McKenna WJ. Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol 1996; 54: 157-63.
182. [182] Cunningham MW, Hall NK, Krisher KK, Spanier AM. A study of anti-group A streptococcal monoclonal antibodies cross-reactive with myosin. J Immunol 1986; 136: 293-8.
183. [183] Cardoso RN, Macedo FY, Garcia MN, et al. Chagas' cardiomyopa-thy is associated with higher incidence of stroke: a meta-analysis of observational studies. J Card Fail 2014; 20(12): 931-8.
184. [184] Sterin-Borda L, Cossio PM, Gimeno MF, et al. Effect of chagasic sera on the rat isolated atrial preparation: immunological, morphological and function aspects. Cardiovasc Res 1976; 10: 613-22.
185. [185] Wallukat G, Wollenberger A. Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopa-thy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta 1987; 46: S634-9.
186. [186] Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999; 99: 649-54.
187. [187] Baba A, Yoshikawa T, Fukuda Y, et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 2004; 25: 1108-15.
188. [188] Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epi-topes in the first and second extracellular loops. J Mol Cell Cardiol 1995; 27: 397-406.
189. [189] Fu ML, Schulze W, Wallukat G, Hjalmarson A, Hoebeke J. Functional epitope analysis of the second extracellular loop of the human heart muscarinic acetylcholine receptor. J Mol Cell Cardiol. 1995; 27: 427-36.
190. [190] Elies R, Ferrari I, Wallukat G, et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoan-tibodies in patients with Chagas' disease. J Immunol 1996; 157: 4203-11.
191. [191] Ferrari I, Levin MJ, Wallukat G, et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med 1995; 182: 59-65.
192. [192] Levin MJ, Hoebeke J. Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease. Autoimmunity 2008; 41: 429-33.
193. [193] Mahler E, Sepulveda P, Jeannequin O, et al. A monoclonal antibody against the immunodominant epitope of the ribosomal P2beta protein of Trypanosoma cruzi interacts with the human beta 1-adrenergic receptor. Eur J Immunol 2001; 31: 2210-6.
194. [194] Pei J, Li N, Chen J, et al. The predictive values of beta1-adrenergic and M2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure. Eur J Heart Fail 2012; 14: 887-94.
195. [195] Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 418-24.
196. [196] Stork S, Boivin V, Horf R, et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006; 152: 697-704.
197. [197] Chiale PA, Ferrari I, Mahler E, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001; 103: 1765-71.
198. [198] Talvani A, Rocha MO, Ribeiro AL, Borda E, Sterin-Borda L, Teixeira MM. Levels of anti-M2 and anti-beta1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas' heart disease. Microbes Infect 2006; 8: 2459-64.
199. [199] Ribeiro AL, Gimenez LE, Hernandez CC, et al. Early occurrence of anti-muscarinic autoantibodies and abnormal vagal modulation in Chagas disease. Int J Cardiol 2007; 117: 59-63.
200. [200] Stavrakis S, Kem DC, Patterson E, et al. Opposing cardiac effects of autoantibody activation of beta-adrenergic and M2 muscarinic receptors in cardiac-related diseases. Int J Cardiol 2011; 148: 331-6.
201. [201] Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 1153-9.
202. [202] Deubner N, Berliner D, Schlipp A, et al. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail 2010; 12: 753-62.
203. [203] Jahns R, Boivin V, Hein L, et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idio-pathic dilated cardiomyopathy. J Clin Invest 2004; 113: 1419-29.
204. [204] Matsui S, Fu ML, Hayase M, et al. Active immunization of combined beta1-adrenoceptor and M2-muscarinic receptor peptides induces cardiac hypertrophy in rabbits. J Card Fail. 1999; 5: 246-54.
205. [205] Freedman NJ, Lefkowitz RJ. Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 2004; 113: 1379-82.
206. [206] Jane-wit D, Altuntas CZ, Johnson JM, et al. Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonis-tically inducing cardiomyocyte apoptosis. Circulation 2007; 116: 399-410.
207. [207] Liu J, Mao W, Iwai C, et al. Adoptive passive transfer of rabbit beta1-adrenoceptor peptide immune cardiomyopathy into the Rag2-/- mouse: participation of the ER stress. J Mol Cell Cardiol 2008; 44: 304-14.
208. [208] Liang CS, Mao W, Liu J. Pro-apoptotic effects of anti-beta1-adrenergic receptor antibodies in cultured rat cardiomyocytes: actions on endoplasmic reticulum and the prosurvival PI3K-Akt pathway. Autoimmunity. 2008; 41: 434-41.
209. [209] Lee HC, Huang KT, Wang XL, Shen WK. Autoantibodies and cardiac arrhythmias. Heart Rhythm. 2011; 8: 1788-95.
210. [210] Katz A, Lifshitz Y, Bab-Dinitz E, et al. Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. J Biol Chem 2010; 285: 19582-92.
211. [211] Nesher M, Shpolansky U, Rosen H, Lichtstein D. The digitalis-like steroid hormones: new mechanisms of action and biological significance. Life Sci 2007; 80: 2093-107.
212. [212] Wasserstrom JA, Aistrup GL. Digitalis: new actions for an old drug. Am J Physiol Heart Circ Physiol 2005; 289: H1781-93.
213. [213] Patel PA, Hernandez AF. Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy. Eur J Heart Fail 2013; 15: 724-9.
214. [214] Baba A, Akaishi M, Shimada M, et al. Complete elimination of cardiodepressant IgG3 autoantibodies by immunoadsorption in patients with severe heart failure. Circ J 2010; 74: 1372-8.
215. [215] Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoadsorption in beta(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail 2012; 14: 1374-88.
216. [216] Schimke I, Muller J, Dandel M, et al. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. J Clin Apher 2005; 20: 137-42.
217. [217] Haberland A, Wallukat G, Dahmen C, Kage A, Schimke I. Ap-tamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res 2011; 109: 986-92.
218. [218] Wallukat G, Haberland A, Berg S, et al. The first aptamer-apheresis column specifically for clearing blood of beta1-receptor autoantibodies. Circ J 2012; 76: 2449-55.
219. [219] Santosh B, Yadava PK. Nucleic acid aptamers: research tools in disease diagnostics and therapeutics. Biomed Res Int 2014; 2014: 540451.
220. [220] Munch G, Boivin-Jahns V, Holthoff HP, et al. Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012; 14: 1230-9.
221. [221] Issa VS, Amaral AF, Cruz FD, et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail. 2010; 3: 82-8.
222. 222[] Quiros FR, Morillo CA, Casas JP, Cubillos LA, Silva FA. CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Cha-gas cardiomyopathy[NCT00323973]. Trials 2006; 7: 21.
223. [223] Bestetti RB, Otaviano AP, Cardinalli-Neto A, da Rocha BF, Theodoropoulos TA, Cordeiro JA. Effects of B-Blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure. Int J Cardiol 2011; 151: 205-8.
224. [224] Vicco MH, Pujato N, Bontempi I, Rodeles L, Marcipar I, Bottasso OA. beta1-selective adrenoceptor antagonists increase plasma levels of anti-p2beta antibodies and decrease cardiac involvement in chronic progressive Chagas heart disease. Can J Cardiol 2014; 30: 332-7.
225. [225] McLean BA, Oudit GY. Role of autoimmunity in heart disease: is Chagas heart disease the definitive proof? Can J Cardiol 2014; 30: 267-9.
226. [226] Marcus GM, Smith LM, Ordovas K, et al. Intracardiac and ex-tracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 2010; 7: 149-54.
227. [227] Maixent JM, Paganelli F, Scaglione J, Levy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: 612-7.
228. [228] Stavrakis S, Yu X, Patterson E, et al. Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. J Am Coll Cardiol. 2009; 54: 1309-16.
229. [229] Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-18.
230. [230] McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med 2010; 362: 228-38.
231. [231] Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Trans- lational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-16.
232. [232] Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J. 1956; 51: 533-41.
233. [233] Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984; 101: 370-7.
234. [234] Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-86.
235. [235] Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
236. [236] Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J. 2003; 24: 2161-3.
237. 237[] Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005; 95: 3C-8C; discussion 38C-40C.
238. [238] Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358: 2148-59.
239. [239] Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996; 2: 243-9.
240. [240] Petersen JW, Felker GM. Inflammatory biomarkers in heart failure. Congest Heart Fail 2006; 12: 324-8.
241. [241] Jahns R, Boivin V, Lohse MJ. beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med 2006; 16: 20-4.
242. [242] Kaya Z, Katus HA, Rose NR. Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol 2010; 134: 80-8.
243. [243] Dungen HD, Platzeck M, Vollert J, et al. Autoantibodies against cardiac troponin I in patients with congestive heart failure. Eur J Heart Fail 2010; 12: 668-75.
244. [244] Leuschner F, Li J, Goser S, et al. Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction. Eur Heart J 2008; 29: 1949-55.
245. 245[] Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Car-diol 2005; 95: 17C-23C; discussion 38C-40C.
246. [246] Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220-5.
247. [247] Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-602.
248. [248] Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (EN-BREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-7.
249. [249] Sliwa K, Woodiwiss A, Kone VN, et al. Therapy of ischemic car-diomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004; 109: 750-5.
250. [250] Smith PK, Shernan SK, Chen JC, et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg 2011; 142: 89-98.
251. [251] Veljkovic V, Glisic S, Veljkovic N, et al. Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism. Vaccine 2014; 32(48): 6569-75.